TICKERNERD
Menu
LMATLMATHealthcare · Medical Instruments & Supplies

LMAT Stock Forecast: LeMaitre Vascular, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$81
+2.57% on the day

The 8 Wall Street analysts covering LeMaitre Vascular, Inc. hold a median 12-month price target of $100 — +23.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 3 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
70 / 100
Median analyst target
$100
Analysts covering
8
Revenue$70.4M+9.6% y/y
Operating income$20.4M
Net income$17.1M
Free cash flow$13.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.6%
1M
+0.4%
YTD
+0.6%
1Y
−6.9%
From 52W high
−30.6%
From 52W low
+2.8%
$79
$117
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LMAT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LeMaitre Vascular, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
70 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Quality
88
Growth
78
Value
78
Momentum
55
Accruals
48
Issuance
44
Revisions
40
Size
37

Volatility (96): The share price has been relatively steady.

Revisions (40): Analysts have, on balance, been cutting their forecasts.

Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LMAT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LMAT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$90$100$110$120$130$140Jan 26Apr 26Jul 26Oct 26LMATHigh $132Median $100Low $81

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
4 Buy4 Hold0 Sell
Low $81Median $100High $132

The green dot is the last close — the median target sits +23.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026Wells FargoMaintainsEqual-Weight$104 → $94
3 June 2026Barrington ResearchMaintainsOutperform$120
3 June 2026Barrington ResearchMaintainsOutperform—
6 May 2026Barrington ResearchMaintainsOutperform—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026Wells FargoMaintainsEqual-Weight—
26 Feb 2026Barrington ResearchMaintainsOutperform—
26 Feb 2026CitizensMaintainsMarket Outperform—
26 Feb 2026Roth CapitalReiteratesBuy—
26 Feb 2026Wells FargoMaintainsEqual-Weight—
20 Feb 2026Barrington ResearchMaintainsOutperform—
7 Nov 2025Wells FargoMaintainsEqual-Weight—
5 Nov 2025Roth CapitalReinstatesBuy$108
15 Oct 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
6 Aug 2025Barrington ResearchUpgradeOutperform—
6 Aug 2025Cantor FitzgeraldMaintainsNeutral—
22 July 2025Barrington ResearchReiteratesMarket Perform—
28 Feb 2025Barrington ResearchDowngradeMarket Perform—
28 Feb 2025Citizens Capital MarketsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LMAT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LMAT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, LeMaitre Vascular, Inc. returned −6.9% against +16.2% for the S&P 500, dividends included.

LMAT vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26LMATS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LMAT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.0%
Analysts raising
0
Analysts cutting
8
Fundamentals

LeMaitre Vascular, Inc. (LMAT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.7×

Cheaper than 27% of US stocks

Price / sales
6.9×

Cheaper than 19% of US stocks

Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
19.5×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
9.6%

Higher than 51% of US stocks

Earnings growth (YoY)
23.7%

Higher than 62% of US stocks

Gross margin
72.1%

Higher than 84% of US stocks

Operating margin
29.0%

Higher than 86% of US stocks

Net margin
25.0%

Higher than 86% of US stocks

Returns & dividend
Return on equity
16.8%

Higher than 77% of US stocks

Return on assets
7.4%

Higher than 86% of US stocks

Dividend yield
1.3%

Higher than 56% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

LeMaitre Vascular, Inc. (LMAT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LeMaitre Vascular, Inc. has a market value of $1.8B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $262.4M. The latest quarter grew 9.6% year on year.

  • Net income over the same four quarters: $65.7M, a 25.0% net margin.

  • Diluted earnings per share, trailing twelve months: $2.85.

  • Free cash flow in the twelve months to 30 June 2026: $73.8M.

  • LeMaitre Vascular, Inc. spent $20.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 22.9M.

  • Trailing P/E: 27.7×; forward P/E: 24.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.27%, paying out 32% of earnings.

  • LeMaitre Vascular, Inc. employs 646 people — $406K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

LMAT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
LMATLeMaitre Vascular, Inc.$1.8B
70
BLFSBioLife Solutions, Inc.$1.8B
91
AZTAAzenta, Inc.$1.8B
83
XRAYDentsply Sirona, Inc.$1.7B
90
KMTSKestra Medical Technologies Ltd.$1.6B
25
ATRCAtriCure, Inc.$2.8B
94
STAASTAAR Surgical Co.$1.1B
70

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LeMaitre Vascular, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LMAT news & analysis

LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine

Seeking Alpha · 1 Oct 2026positive

Seeking Alpha discusses LeMaitre Vascular's shift to larger, higher-multiple acquisitions, which has raised its success rate to 80% and boosted gross margins from 65% to 72%. The company holds roughly $376M in cash and short-term investments, supporting its disciplined, accretive deal-making strategy despite a reported Q2 miss.

Why it matters — LMAT watchers would care because the article frames the acquisition-focused strategy and margin expansion as durable growth drivers for the company.

PAHC or LMAT: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 2 Sept 2026neutral

A Zacks Investment Research article compares LeMaitre Vascular (LMAT) with Phibro Animal Health (PAHC) as potential value investments within the Medical - Products sector, examining which stock is more attractive to value investors.

Why it matters — LMAT watchers may gain insight into how the company is being evaluated against a sector peer from a value-investing perspective.

LeMaitre to Participate at Upcoming Investor Conferences in September

GlobeNewsWire · 27 Aug 2026neutral

LeMaitre Vascular announced that management will participate in three upcoming investor conferences in September. The announcement was made on August 27, 2026.

Why it matters — LMAT watchers may be interested because management participation at investor conferences could provide opportunities for company updates and engagement with the investment community.

Dividend Champion, Contender, And Challenger Highlights: Week August 16

Seeking Alpha · 14 Aug 2026neutral

A Seeking Alpha article provides a weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers, noting companies that changed their dividends and those with upcoming ex-dividend dates.

Why it matters — LMAT watchers may find the update relevant if LeMaitre Vascular is mentioned among the dividend-paying companies tracked in these categories.

GEHC or LMAT: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 13 Aug 2026neutral

Zacks Investment Research published a piece comparing GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT) to determine which Medical Products stock presents the better value opportunity for investors at this time.

Why it matters — The comparison places LeMaitre Vascular's valuation and investment profile directly against a major industry peer, offering context for how the company is perceived in the medical-products sector.

FAQ

Frequently asked questions about LMAT stock

What is the LMAT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering LeMaitre Vascular, Inc. have a median 12-month price target of $100, with estimates ranging from $81 to $132. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LMAT stock a buy right now?

Of the 8 analysts covering LeMaitre Vascular, Inc., 4 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeMaitre Vascular, Inc. 70 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LMAT?

As at 3 Oct 2026, LeMaitre Vascular, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will LMAT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +23.5% from the last close, and Ticker Nerd's factor model ranks LeMaitre Vascular, Inc. 70 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LMAT stock forecast for 2030?

No analyst covering LeMaitre Vascular, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $132 over the next 12 months.

How has LMAT stock performed over the past year?

LeMaitre Vascular, Inc. returned -6.9% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LeMaitre Vascular, Inc. do?

LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease.

What is the latest news on LMAT?

The most recent item we track (Seeking Alpha, 1 Oct 2026): "LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine". Seeking Alpha discusses LeMaitre Vascular's shift to larger, higher-multiple acquisitions, which has raised its success rate to 80% and boosted gross margins from 65% to 72%. The company holds roughly $376M in cash and short-term investments, supporting its disciplined, accretive deal-making strategy despite a reported Q2 miss.

Company

About LeMaitre Vascular, Inc.

LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease. The company develops, manufactures, and markets a specialized portfolio that includes biologic patches, vascular grafts, catheters, carotid shunts, valvulotomes, radiopaque marking tape, and other disposable and implantable tools used to repair blood vessels and support bypass, access, and clot-removal procedures. LeMaitre Vascular also provides human tissue cryopreservation services for implantation, adding a complementary service component to its device business. Its offerings are used by vascular surgeons and related specialists in hospitals and surgical settings, giving the company a focused role in a niche segment of the broader medical technology market.

CEO Mr. George W. LeMaitre · 646 employees · United States · https://www.lemaitre.com